公开(公告)号：US20130115602A1

公开(公告)日：2013-05-09

申请号：US13727427

申请日：2012-12-26

Applicant: Biomerieux

Inventor： Frederic BESEME ,  Jean-Luc BLOND ,  Olivier BOUTON ,  Bernard MANDRAND ,  Francois MALLET ,  Herve PERRON

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K38/00 ,  A61K39/00 ,  C07K14/005 ,  C12N2740/10022 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/564 ,  G01N2800/24

Abstract: A genomic retroviral nucleic material, in an isolated or purified state, at least partially functional or non-functional, wherein the genome comprises a reference nucleotide sequence selected from the group including sequences of SEQ ID NOs: 1-15, their complementary sequences, and their equivalent sequences, in particular, nucleotide sequences having, for every series of 100 contiguous monomers, at least 70% and preferably at least 90% homology with the sequences of SEQ ID NOs: 1-15.

Abstract translation: 一种分离或纯化的基因组逆转录病毒核酸，至少部分是功能性或非功能性的，其中所述基因组包含参考核苷酸序列，其选自SEQ ID NO：1-15的序列，其互补序列和 它们的等同序列，特别是对于每个100个连续单体的系列，具有与SEQ ID NO：1-15的序列至少70％，优选至少90％的同源性的核苷酸序列。

公开(公告)号：US20140349875A1

公开(公告)日：2014-11-27

申请号：US14330535

申请日：2014-07-14

Applicant: BIOMERIEUX

Inventor： Juliette GIMENEZ ,  Cecile MONTGIRAUD ,  Francois MALLET

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/686 ,  C12Q1/702 ,  C12Q2535/125 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: A method for in vitro diagnosis of testicular cancer includes (i) obtaining a biological sample from a patient suspected of having testicular cancer, (ii) performing an assay to determine the methylation status of CpG dinucleotides in a genomic DNA target sequence, the DNA target sequence being the 5′ LTR U3 promoter sequence of the ERVWE1 locus, optionally further including an activator sequence directly upstream of the 5′ LTR U3 promoter sequence, and (iii) diagnosing the patient with testicular cancer when the DNA target sequence is hypomethylated as compared to a methylation status indicative of the absence of testicular cancer.

Abstract translation: 用于体外诊断睾丸癌的方法包括：（i）从疑似患有睾丸癌的患者获得生物样品，（ii）进行测定以确定基因组DNA靶序列中CpG二核苷酸的甲基化状态，DNA靶标 序列是ERVWE1基因座的5'LTR U3启动子序列，任选地还包括直接在5'LTR U3启动子序列上游的激活剂序列，和（iii）当DNA靶序列被低甲基化时诊断患有睾丸癌的患者， 指示缺乏睾丸癌的甲基化状态。

公开(公告)号：US20130172209A1

公开(公告)日：2013-07-04

申请号：US13739447

申请日：2013-01-11

Applicant: BIOMERIEUX

Inventor： Maud ARSAC ,  Bertrand BONNAUD ,  Francois MALLET ,  Jean-Philippe PICHON

IPC: C12Q1/70

CPC classification number: C12Q1/702 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.

Abstract translation: 本发明涉及一种用于体外诊断或睾丸癌预后的方法，其包括从至少一种选自SEQ ID NO：1中鉴定的序列的核酸序列检测至少一种表达产物的存在或不存在的步骤， 6或来自与SEQ ID NO：1至6中鉴定的一个序列具有至少99％同一性的序列，或与分离的核酸序列及其作为睾丸癌标志物的用途的序列。

公开(公告)号：US20160090402A1

公开(公告)日：2016-03-31

申请号：US14847941

申请日：2015-09-08

Applicant: BIOMERIEUX

Inventor： Francois MALLET ,  Guy ORIOL ,  Valerie CHEYNET

IPC: C07K14/005 ,  A61K39/21 ,  C07K16/10 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  C07K16/1036 ,  C07K2317/34 ,  C12N7/00 ,  C12N2740/10022 ,  C12N2740/10034 ,  C12N2740/10063 ,  G01N2333/15

Abstract: A peptide domain necessary for an interaction between an envelope of a virus belonging to an HERV-W interference group and an hASCT receptor comprises (i) an N-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 1 to SEQ ID No. 29, (ii) a C-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 30 to SEQ ID No. 40, and (iii) at least one motif between the N-terminus and the C-terminus, and having an amino acid sequence selected from the group consisting of: SEQ ID No. 41, SEQ ID No. 42 and SEQ ID No. 73.

Abstract translation: 属于HERV-W干扰组的病毒的包膜与hASCT受体之间的相互作用所必需的肽结构域包含（i）具有选自下组的氨基酸序列的N末端基序：SEQ ID No. 1至SEQ ID No.29，（ii）具有选自SEQ ID No.30至SEQ ID No.40的氨基酸序列的C末端基序，和（iii）至少一个位于 N-末端和C-末端，并且具有选自SEQ ID No.41，SEQ ID No.42和SEQ ID No.73的氨基酸序列。